Shattuck Labs Enters $75M At-The-Market Offering Agreement
STTK has more than doubled off its 52-week low of $0.692.
Summary
Shattuck Labs has entered into a sales agreement for an at-the-market offering of up to $75 million in common stock through Leerink Partners. The company intends to use the proceeds to advance its clinical trials and for general corporate purposes.
Key Events · Financing and Capital Events · STTK
-
Enters At-The-Market Offering
Shattuck Labs may offer and sell up to $75 million in shares of its common stock through Leerink Partners LLC.
-
Proceeds Usage
The company intends to use the proceeds to advance its clinical trials and for working capital and general corporate purposes.
Analysis · STTK · Life Sciences
Shattuck Labs has entered into an at-the-market offering agreement with Leerink Partners to sell up to $75 million of its common stock. This agreement allows the company to raise capital over time, but the continuous offering may exert downward pressure on the stock price.
At the time of this filing, STTK was trading at $4.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $275.9M. The 52-week trading range was $0.69 to $4.89. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.